1109 related articles for article (PubMed ID: 18195327)
21. Newly diagnosed breast cancer patients choose bilateral mastectomy over breast-conserving surgery when testing positive for a BRCA1/2 mutation.
Stolier AJ; Corsetti RL
Am Surg; 2005 Dec; 71(12):1031-3. PubMed ID: 16447474
[TBL] [Abstract][Full Text] [Related]
22. Numerous high-risk epithelial lesions in familial breast cancer.
Hoogerbrugge N; Bult P; Bonenkamp JJ; Ligtenberg MJ; Kiemeney LA; de Hullu JA; Boetes C; Niermeijer MF; Brunner HG
Eur J Cancer; 2006 Oct; 42(15):2492-8. PubMed ID: 16908132
[TBL] [Abstract][Full Text] [Related]
23. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Jernström H; Lubinski J; Lynch HT; Ghadirian P; Neuhausen S; Isaacs C; Weber BL; Horsman D; Rosen B; Foulkes WD; Friedman E; Gershoni-Baruch R; Ainsworth P; Daly M; Garber J; Olsson H; Sun P; Narod SA
J Natl Cancer Inst; 2004 Jul; 96(14):1094-8. PubMed ID: 15265971
[TBL] [Abstract][Full Text] [Related]
24. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
[TBL] [Abstract][Full Text] [Related]
25. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer.
Pierce LJ; Levin AM; Rebbeck TR; Ben-David MA; Friedman E; Solin LJ; Harris EE; Gaffney DK; Haffty BG; Dawson LA; Narod SA; Olivotto IA; Eisen A; Whelan TJ; Olopade OI; Isaacs C; Merajver SD; Wong JS; Garber JE; Weber BL
J Clin Oncol; 2006 Jun; 24(16):2437-43. PubMed ID: 16636335
[TBL] [Abstract][Full Text] [Related]
26. Decision-making process of women carrying a BRCA1 or BRCA2 mutation who have chosen prophylactic mastectomy.
McQuirter M; Castiglia LL; Loiselle CG; Wong N
Oncol Nurs Forum; 2010 May; 37(3):313-20. PubMed ID: 20439215
[TBL] [Abstract][Full Text] [Related]
27. Prophylactic bilateral mastectomy: patterns of practice.
Metcalfe KA; Goel V; Lickley L; Semple J; Narod SA
Cancer; 2002 Jul; 95(2):236-42. PubMed ID: 12124821
[TBL] [Abstract][Full Text] [Related]
28. Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation.
Hermsen BB; Verheijen RH; Menko FH; Gille JJ; van Uffelen K; Blankenstein MA; Meijer S; van Diest PJ; Kenemans P; von Mensdorff-Pouilly S
Eur J Cancer; 2007 Jul; 43(10):1556-63. PubMed ID: 17532207
[TBL] [Abstract][Full Text] [Related]
29. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series.
Robson M; Svahn T; McCormick B; Borgen P; Hudis CA; Norton L; Offit K
Cancer; 2005 Jan; 103(1):44-51. PubMed ID: 15558796
[TBL] [Abstract][Full Text] [Related]
30. Histopathological findings and follow-up after prophylactic mastectomy and immediate breast reconstruction in 100 women from families with hereditary breast cancer.
Isern AE; Loman N; Malina J; Olsson H; Ringberg A
Eur J Surg Oncol; 2008 Oct; 34(10):1148-54. PubMed ID: 18434071
[TBL] [Abstract][Full Text] [Related]
31. Preventive surgery is associated with reduced cancer risk and mortality in women with BRCA1 and BRCA2 mutations.
Domchek SM; Rebbeck TR
LDI Issue Brief; 2010; 16(2):1-4. PubMed ID: 21545057
[TBL] [Abstract][Full Text] [Related]
32. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
Metcalfe KA; Lynch HT; Ghadirian P; Tung N; Olivotto IA; Foulkes WD; Warner E; Olopade O; Eisen A; Weber B; McLennan J; Sun P; Narod SA
Gynecol Oncol; 2005 Jan; 96(1):222-6. PubMed ID: 15589605
[TBL] [Abstract][Full Text] [Related]
33. Contralateral Prophylactic Mastectomy Overtreatment: Expectations from Personal Genomics for Tailored Breast Cancer Surgery.
Zografos GC; Roukos DH
Ann Surg Oncol; 2010 Mar; 17(3):939; author reply 940. PubMed ID: 19937131
[No Abstract] [Full Text] [Related]
34. Preoperative risk assessment among women undergoing bilateral prophylactic mastectomy for cancer risk reduction.
Rueth NM; McMahon M; Arrington AK; Swenson K; Leach J; Tuttle TM
Ann Surg Oncol; 2011 Sep; 18(9):2515-20. PubMed ID: 21424371
[TBL] [Abstract][Full Text] [Related]
35. Surgical decisions made by 158 women with hereditary breast cancer aged <50 years.
Evans DG; Lalloo F; Hopwood P; Maurice A; Baildam A; Brain A; Barr L; Howell A
Eur J Surg Oncol; 2005 Dec; 31(10):1112-8. PubMed ID: 16005602
[TBL] [Abstract][Full Text] [Related]
36. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.
Metcalfe KA; Birenbaum-Carmeli D; Lubinski J; Gronwald J; Lynch H; Moller P; Ghadirian P; Foulkes WD; Klijn J; Friedman E; Kim-Sing C; Ainsworth P; Rosen B; Domchek S; Wagner T; Tung N; Manoukian S; Couch F; Sun P; Narod SA;
Int J Cancer; 2008 May; 122(9):2017-22. PubMed ID: 18196574
[TBL] [Abstract][Full Text] [Related]
37. Decision making regarding prophylactic mastectomy: stability of preferences and the impact of anticipated feelings of regret.
van Dijk S; van Roosmalen MS; Otten W; Stalmeier PF
J Clin Oncol; 2008 May; 26(14):2358-63. PubMed ID: 18467728
[TBL] [Abstract][Full Text] [Related]
38. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations.
Fatouros M; Baltoyiannis G; Roukos DH
Ann Surg Oncol; 2008 Jan; 15(1):21-33. PubMed ID: 17940826
[TBL] [Abstract][Full Text] [Related]
39. Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation.
Metcalfe KA; Poll A; O'Connor A; Gershman S; Armel S; Finch A; Demsky R; Rosen B; Narod SA
Clin Genet; 2007 Sep; 72(3):208-17. PubMed ID: 17718858
[TBL] [Abstract][Full Text] [Related]
40. Prophylactic mastectomy in familial breast carcinoma. What do the pathologic findings learn us?
Leunen K; Drijkoningen M; Neven P; Christiaens MR; Van Ongeval C; Legius E; Amant F; Berteloot P; Vergote I
Breast Cancer Res Treat; 2008 Jan; 107(1):79-86. PubMed ID: 17431765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]